Pharmaceutical Executive-06-01-2013

Pharmaceutical Executive
Column

June 01, 2013

Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.

Pharmaceutical Executive
From the Editor

June 01, 2013

Getting patients to take their medicine on spec and on time is the challenge that never goes away-it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.

Pharmaceutical Executive

What is really driving decision making by the new Brazilian HTA agency? A look at appraisals issued in the first year.

Pharmaceutical Executive

New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. The question is will Big Pharma be flexible enough to keep pace with the changes?

Pharmaceutical Executive

The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.

Pharmaceutical Executive
Country Report

June 01, 2013

Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eyecatching. As reported by the IDA, nine out of the top 10 pharma companies in the world have substantial manufacturing operations in Ireland.

Pharmaceutical Executive

Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage.

Pharmaceutical Executive

S

Pharmaceutical Executive

Compounders are under increased scrutiny following last year's spinal meningitis outbreak.

Pharmaceutical Executive
Features

June 01, 2013

Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo.

Pharmaceutical Executive
Column

June 01, 2013

Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery.